Associations of circulating dimethylarginines with the metabolic syndrome in the Framingham Offspring study
Open Access
- 7 September 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (9) , e0254577
Abstract
Background: Circulating levels of the endogenous inhibitor of nitric oxide synthase, asymmetric dimethylarginine (ADMA), are positively associated with the prevalence of metabolic syndrome (MetS) in cross-sectional investigations. It is unclear if circulating ADMA and other methylarginines are associated with incident MetS prospectively. Methods: We related circulating ADMA, symmetric dimethylarginine (SDMA), L-arginine (ARG) concentrations (measured with a validated tandem mass spectrometry assay) and the ARG/ADMA ratio to MetS and its components in 2914 (cross-sectional analysis, logistic regression; mean age 58 years, 55% women) and 1656 (prospective analysis, Cox regression; mean age 56 years, 59% women) individuals from the Framingham Offspring Study who attended a routine examination. Results: Adjusting for age, sex, smoking, and eGFR, we observed significant associations of ADMA (direct) and ARG/ADMA (inverse) with odds of MetS (N = 1461 prevalent cases; Odds Ratio [OR] per SD increment 1.13, 95%CI 1.04–1.22; and 0.89, 95%CI 0.82–0.97 for ADMA and ARG/ADMA, respectively). Upon further adjustment for waist circumference, systolic and diastolic blood pressure, glucose, high-density lipoprotein cholesterol, and triglycerides, we observed a positive relation between SDMA and MetS (OR per SD increment 1.15, 95% CI 1.01–1.30) but the other associations were rendered statistically non-significant. We did not observe statistically significant associations between any of the methylarginines and the risk of new-onset MetS (752 incident events) over a median follow-up of 11 years. Conclusion: It is unclear whether dimethylarginines play an important role in the incidence of cardiometabolic risk in the community, notwithstanding cross-sectional associations. Further studies of larger samples are needed to replicate our findings.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (Bo1431/4-1)
- National Heart, Lung, and Blood Institute (N01-HC-25195)
- National Heart, Lung, and Blood Institute (HHSN268201500001I)
- National Heart, Lung, and Blood Institute (75N92019D00031)
- National Heart, Lung, and Blood Institute (5T32HL125232)
This publication has 50 references indexed in Scilit:
- Asymmetric Dimethylarginine Plasma Levels and Endothelial Function in Newly Diagnosed Type 2 Diabetic PatientsInternational Journal of Molecular Sciences, 2012
- Connection between Telomerase Activity in PBMC and Markers of Inflammation and Endothelial Dysfunction in Patients with Metabolic SyndromePLOS ONE, 2012
- Symmetric Dimethylarginine as a Proinflammatory Agent in Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2011
- Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the CommunityCirculation, 2009
- Dimethylarginine Dimethylaminohydrolase Overexpression Enhances Insulin SensitivityArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Metabolic syndrome and risk of incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition-Potsdam StudyCardiovascular Diabetology, 2008
- Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndromeInternational Journal of Cardiology, 2007
- Effect of asymmetric dimethylarginine on atherogenesis and erythrocyte deformability in apolipoprotein E deficient miceLife Sciences, 2007
- Diagnosis and Management of the Metabolic SyndromeCirculation, 2005
- Testing Endothelial Vasomotor FunctionCirculation, 2003